[EN] BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6<br/>[FR] INHIBITEURS DE BCL6 DÉRIVÉS DE BENZIMIDAZOLONE
申请人:CANCER RESEARCH TECH LTD
公开号:WO2018215801A1
公开(公告)日:2018-11-29
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
本发明涉及作为BCL6(B细胞淋巴瘤6)活性抑制剂的Formula I化合物:其中X1、X2、R1、R2和R3如本文所定义。本发明还涉及制备这些化合物的方法,包括含有它们的药物组合物,以及它们在治疗增生性疾病(如癌症)以及BCL6活性有所涉及的其他疾病或病况中的用途。